Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

O. Ottmann · SciRah

Researcher profile · Semantic Scholar

O. Ottmann

Share profile

O. Ottmann — researcher profile on SciRah

h-index: 78
Works: 483
Citations: 29K

Most-cited papers

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
J. Cortes, Florian H. Heidel, A. Hellmann, W. Fiedler +13 more
2018Leukemia447 citations Open access
Semantic Scholar
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.
G. Martinelli, N. Boissel, P. Chevallier, O. Ottmann +9 more
2017Journal of Clinical Oncology377 citations Open access
Semantic Scholar
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
Timothy P. Hughes, Michael J. Mauro, Jorge E. Cortes, H. Minami +26 more
2019New England Journal of Medicine359 citations Open access
Semantic Scholar
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL.
P. Rousselot, M. Coudé, N. Gokbuget, Carlo Gambacorti Passerini +32 more
2016Blood293 citations Open access
Semantic Scholar
CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies
A. Romanski, C. Uherek, G. Bug, E. Seifried +4 more
2016Journal of Cellular and Molecular Medicine206 citations Open access
Semantic Scholar
CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells.
Mateusz Legut, G. Dolton, A. Mian, O. Ottmann +1 more
2018Blood200 citations Open access
Semantic Scholar
Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.
G. Baerlocher, Elisabeth Oppliger Leibundgut, O. Ottmann, G. Spitzer +7 more
2015New England Journal of Medicine197 citations Open access
Semantic Scholar
Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
S. Oelsner, M. Friede, Congcong Zhang, J. Wagner +7 more
2017Cytotherapy170 citations Open access
Semantic Scholar
Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy.
G. Dolton, C. Rius, A. Wall, Barbara Szomolay +29 more
2023Cell138 citations Open access
Semantic Scholar
Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML
Faisal Basheer, G. Giotopoulos, Eshwar Meduri, Hai-Yang Yun +20 more
2019Journal of Experimental Medicine106 citations Open access
Semantic Scholar
Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy.
I. Nagel, M. Bartels, J. Duell, H. Oberg +15 more
2017Blood88 citations Open access
Semantic Scholar
Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia
N. Gokbuget, G. Zugmaier, M. Klinger, P. Kufer +10 more
2017Haematologica87 citations Open access
Semantic Scholar
Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study.
G. Martinelli, N. Boissel, P. Chevallier, O. Ottmann +7 more
2021European Journal of Cancer86 citations Open access
Semantic Scholar
Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial
M. Konopleva, C. Röllig, J. Cavenagh, D. Deeren +23 more
2022Blood Advances78 citations Open access
Semantic Scholar
Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
U. Borate, J. Esteve, K. Porkka, S. Knapper +19 more
2019Blood78 citations
Semantic Scholar
Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation.
H. Pfeifer, Katharina Raum, S. Marković, V. Nowak +19 more
2018Blood74 citations
Semantic Scholar
Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome–positive B‐precursor acute lymphoblastic leukemia
A. Rambaldi, J. Ribera, H. Kantarjian, H. Dombret +6 more
2019Cancer70 citations Open access
Semantic Scholar
A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts
G. Garcia-Manero, M. Sekeres, M. Egyed, M. Breccia +18 more
2017Leukemia69 citations Open access
Semantic Scholar
Phase 1/1B trial of the heat shock protein 90 inhibitor NVP‐AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma
R. Seggewiss-Bernhardt, R. Bargou, Y. Goh, A. Stewart +9 more
2015Cancer64 citations Open access
Semantic Scholar
Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study
A. Brunner, J. Esteve, K. Porkka, S. Knapper +20 more
202062 citations
Semantic Scholar
Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial
Jennifer R. Brown, M. Hamadani, J. Hayslip, A. Janssens +17 more
2018The Lancet Haematology60 citations Open access
Semantic Scholar
A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors
N. Haense, A. Atmaca, C. Pauligk, K. Steinmetz +7 more
2016BMC Cancer59 citations Open access
Semantic Scholar
Chimeric antigen receptor‐engineered cytokine‐induced killer cells overcome treatment resistance of pre‐B‐cell acute lymphoblastic leukemia and enhance survival
S. Oelsner, J. Wagner, M. Friede, Verena Pfirrmann +9 more
2016International Journal of Cancer59 citations Open access
Semantic Scholar
Mitotic arrest and slippage induced by pharmacological inhibition of Polo‐like kinase 1
M. Raab, Andrea Krämer, S. Hehlgans, M. Sanhaji +8 more
2015Molecular Oncology56 citations Open access
Semantic Scholar
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results
M. Mauro, T. Hughes, Dong-Wook Kim, D. Réa +22 more
2023Leukemia51 citations Open access
Semantic Scholar
Complete Molecular and Hematologic Response in Adult Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) Following Treatment with Blinatumomab: Results from a Phase 2 Single-Arm, Multicenter Study (ALCANTARA)
G. Martinelli, H. Dombret, P. Chevallier, O. Ottmann +6 more
201551 citations
Semantic Scholar
Nilotinib (Tasigna®) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1-Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02)
O. Ottmann, H. Pfeifer, J. Cayuela, K. Spiekermann +21 more
2018Blood44 citations Open access
Semantic Scholar
A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia
F. Lang, L. Wunderle, Susanne Badura, E. Schleyer +9 more
2020BMC Pharmacology and Toxicology31 citations Open access
Semantic Scholar
Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial
H. Döhner, A. Symeonidis, D. Deeren, J. Demeter +26 more
2021HemaSphere30 citations Open access
Semantic Scholar
Phase I dose‐escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia
O. Ottmann, C. Müller-Tidow, A. Krämer, R. Schlenk +9 more
2018British Journal of Haematology28 citations Open access
Semantic Scholar
Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
O. Ottmann, G. Saglio, J. Apperley, C. Arthur +9 more
2018Blood Cancer Journal28 citations Open access
Semantic Scholar
Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study
A. Giagounidis, U. Platzbecker, U. Germing, K. Götze +12 more
201528 citations
Semantic Scholar
Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy
T. Hughes, Y. Goh, O. Ottmann, H. Minami +17 more
201627 citations Open access
Semantic Scholar
Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trials
R. Schlenk, J. Krauter, E. Raffoux, K. Kreuzer +11 more
2018Haematologica26 citations Open access
Semantic Scholar
ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy
O. Ottmann, G. Alimena, D. DeAngelo, Y. Goh +14 more
201525 citations Open access
Semantic Scholar
Tinkering under the Hood: Metabolic Optimisation of CAR-T Cell Therapy
Yasmin R. Jenkins, J. Zabkiewicz, O. Ottmann, Nicholas Jones
2021Antibodies21 citations Open access
Semantic Scholar
PHASE III RANDOMIZED TRIAL OF VOLASERTIB PLUS LOW-DOSE CYTARABINE (LDAC) VERSUS PLACEBO PLUS LDAC IN PATIENTS AGED >= 65 YEARS WITH PREVIOUSLY UNTREATED AML, INELIGIBLE FOR INTENSIVE THERAPY
H. Döhner, A. Symeonidis, M. Sanz, D. Deeren +26 more
201621 citations
Semantic Scholar
Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia
M. Byrne, M. Frattini, O. Ottmann, Ioannis Mantzaris +8 more
2018Blood20 citations Open access
Semantic Scholar
Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia
F. Thol, M. Scherr, Aylin Kirchner, R. Shahswar +21 more
2015Haematologica19 citations Open access
Semantic Scholar
Blockade of thymic stromal lymphopoietin (TSLP) receptor inhibits TSLP-driven proliferation and signalling in lymphoblasts from a subset of B-precursor ALL patients.
T. Vetter, A. Borowski, A. Wohlmann, N. Ranjan +4 more
2016Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis18 citations
Semantic Scholar
PF-114: A 4th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1T315I
A. Turkina, O. Vinogradova, E. Lomaia, E. Shatokhina +17 more
2019Blood17 citations
Semantic Scholar
Phase I/II Study of the Deacetylase Inhibitor Panobinostat As Maintenance Therapy after an Allogeneic Stem Cell Transplantation in Patients with High-Risk MDS or AML: The Panobest-Trial
G. Bug, A. Burchert, E. Wagner, N. Kroeger +8 more
201517 citations
Semantic Scholar
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K
A. Mian, I. Haberbosch, Hazem Khamaisie, A. Agbarya +9 more
2021Annals of Hematology15 citations Open access
Semantic Scholar
Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study.
H. Kantarjian, F. Giles, K. Bhalla, Javier Pinilla +6 more
2016Journal of Clinical Oncology15 citations
Semantic Scholar
Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy
A. Turkina, O. Vinogradova, E. Lomaia, E. Shatokhina +17 more
2018Blood14 citations Open access
Semantic Scholar
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
F. Kroschinsky, J. Middeke, M. Janz, G. Lenz +14 more
2020Investigational new drugs13 citations Open access
Semantic Scholar
Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat
E. Leibundgut, M. Haubitz, B. Burington, O. Ottmann +6 more
2020Haematologica13 citations Open access
Semantic Scholar
The phosphatase UBASH3B/Sts-1 is a negative regulator of Bcr-Abl kinase activity and leukemogenesis
A. Mian, I. Baumann, M. Liebermann, F. Grebien +4 more
2019Leukemia12 citations Open access
Semantic Scholar
The Functional Interplay Between the t(9;22)-Associated Fusion Proteins BCR/ABL and ABL/BCR in Philadelphia Chromosome-Positive Acute Lymphatic Leukemia
Anahita Rafiei, A. Mian, C. Döring, Anna Metodieva +5 more
2015PLoS Genetics12 citations Open access
Semantic Scholar
Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose
A. Wei, J. Esteve, K. Porkka, S. Knapper +22 more
202011 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. DeAngelo×7
Invite
D. DeAngelo — researcher profile on SciRah
N. Gokbuget×6
Invite
N. Gokbuget — researcher profile on SciRah
H. Pfeifer×6
Invite
H. Pfeifer — researcher profile on SciRah
G. Bug×6
Invite
G. Bug — researcher profile on SciRah

×5

Invite

G. Martinelli — researcher profile on SciRah

P. Chevallier×5

Invite

P. Chevallier — researcher profile on SciRah

Invite

F. Lang — researcher profile on SciRah

Invite

H. Döhner — researcher profile on SciRah

Invite

J. Esteve — researcher profile on SciRah

Invite

K. Porkka — researcher profile on SciRah

Invite

J. Janssen — researcher profile on SciRah

Invite

W. Fiedler — researcher profile on SciRah